The risk of secondary myelodysplastic syndromes/acute myeloid leukemia (tMDS/AML) after lymphoma treatment is still a matter of discussion, but a recent review concluded that it may reach 10% within 10 years of primary therapy. 1 Fludarabine-containing regimens have been reported to increase the risk of secondary myeloid neoplasia, particularly when combined with alkylating agents. 2 From our series of 156 lymphoma patients, we identified 19 consecutive patients who had received combination chemotherapy containing fludarabine (25 mg m À2 for days 1-3), plus novantrone (10 mg m À2 for day 1) and dexamethasone (20 mg for days 1-5 every 4 weeks) (FND) or fludarabine (25 mg m À2 for days 1-3) and cyclophosphamide (250 mg m À2 for days 1-3), with or without rituximab (r). Clinical characteristics of the selected cohort are reported in Table 1 .
The mean and median follow-up for the entire group was 53 and 50 months, respectively. Two patients who were lost to follow-up were censored at the time of the last visit. The two cases complicated by secondary myeloid disorder were observed and briefly described.
Case report Case 1. The patient, a 75-year-old man, was diagnosed as having follicular lymphoma grade II, Stage IVA, in July 2001. After informed consent, he entered in a protocol under which he received four cycles of FND-r. He attained complete (molecular) remission and was regularly followed up to June 2005, when he became febrile and was found pancytopenic. Bone marrow biopsy and cytologic examination showed hypoplasia with 20% myeloid blast cells and dysplastic erythroid features. Cytogenetic analysis showed normal karyotype in 10% of metaphases and 90% metaphases with 5,9 and 17 monosomy, extra material on short arm of chromosome 10 and 13, deletion of long arm of chromosome 20 and two markers (46, XY/45, XY; À5, À9, À17, 13p þ , 10p þ , del20q11, þ mar, þ mar). He received lowintensity antileukemic therapy and died 2 months later. 
Comment
The reported incidence of secondary myeloid disorders following fludarabine-containing regimens, which has been reported to be 2.7%, 3 4% 4 and 7.3%, 5 in our series, approached 11%. A period of 44 and 33 months to tAML was comparable to previous observations. Although in patient 2, cyclophosphamide, adryamicin, vincristine and prednisone, and HDCTX may have contributed to AML, in patient 1 as few as four front-line FND-r were followed by leukemic evolution with the complex cytogenetic abnormalities commonly seen in tAML. 6 Base line normal hemogram and morphologic and karyotype analysis performed at the time of initial staging rule out a possible preexisting bone marrow disease.
In a large randomized comparative trial of fludarabine and novantrone versus cyclophosphamide, adryamicin, vincristine and prednisone with and without rituximab, fludarabine and novantrone arm showed higher rates of complete remission and no cases of secondary myelodysplastic syndromes/acute myeloid leukaemia. 7 However, this superiority did not translate into both progression-free survival and overall survival, and follow-up was too short (median 19 months, range 9-37) to detect eventual therapy-related myeloid disorders. 
